Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent

P A Garner-Hamrick1, C Fisher

  • 1Cell and Molecular Biology, Pharmacia and Upjohn, Inc., Kalamazoo, MI 49001, USA.

International Journal of Cancer
|June 4, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.

Heart (British Cardiac Society)·2003
Same author

Transcardiac and transpulmonary gradients in the putative new cardiovascular hormone relaxin.

Heart (British Cardiac Society)·2003
Same author

Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis.

Histopathology·2003
Same author

Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer.

Oral oncology·2003
Same author

Hb Q-India: an uncommon variant diagnosed in three Punjabi patients with diabetes is identified by a novel DNA analysis test.

Journal of clinical pathology·2003
Same author

Imaging features of aggressive angiomyxoma.

Clinical radiology·2003

The study found that cdc25B protein plays a crucial role in S-phase progression in HeLa cells. Inhibiting cdc25B with antisense oligonucleotides led to persistent antiproliferative effects, highlighting its potential as a therapeutic target.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Mammalian cell cycle progression is tightly regulated by cyclin-dependent kinases (cdks).
  • Cdc25 phosphatases (cdc25A, cdc25B, cdc25C) are key activators of cdks, controlling cell cycle transitions.
  • Understanding the specific roles of each cdc25 phosphatase is crucial for comprehending cell cycle regulation.

Purpose of the Study:

  • To investigate the expression patterns of cdc25A, cdc25B, and cdc25C during the HeLa cell cycle.
  • To elucidate the specific function of cdc25B in cell cycle progression, particularly during S-phase.
  • To evaluate the antiproliferative effects of inhibiting cdc25B expression.

Main Methods:

  • Quantitative analysis of cdc25A, cdc25B, and cdc25C mRNA and protein expression in synchronized HeLa cells.

Related Experiment Videos

  • Application of antisense oligonucleotides to specifically reduce cdc25B mRNA levels.
  • Assessment of cell cycle progression using thymidine incorporation assays.
  • Evaluation of the impact of cdc25B inhibition on cell proliferation.

    • Main Results:

    • Cdc25B protein exhibited a unique and restricted expression pattern compared to cdc25A and cdc25C during the HeLa cell cycle.
    • Down-regulation of cdc25B mRNA and protein using antisense oligonucleotides resulted in the inhibition of S-phase progression.
    • Antisense oligonucleotides targeting cdc25B showed no effect on cell cycle progression when applied in early G2-phase.
    • A direct correlation was observed between reduced cdc25B levels and inhibited thymidine incorporation, indicating S-phase arrest.
    • Inhibition of cdc25B demonstrated persistent antiproliferative effects.

    Conclusions:

    • Cdc25B plays a significant role in regulating S-phase progression in mammalian cells.
    • Targeting cdc25B with antisense oligonucleotides can effectively inhibit cell proliferation.
    • These findings suggest that cdc25B is a potential target for antiproliferative therapies.